Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3525 Prognostic factors for progression-free survival (PFS) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

Introduction: SPINET (NCT02683941) evaluated lanreotide autogel/depot (LAN) in metastatic somatostatin receptor (SSTR)-positive typical and atypical (TC and AC) BP NETs.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, prognostic factor, spinet, typical/atypical carcinoid,

#3518 Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

Introduction: SPINET (NCT02683941) evaluated LAN in metastatic somatostatin receptor (SSTR)-positive typical and atypical carcinoid (TC and AC) BP-NETs.

Conference:

Presenting Author: Capdevila J

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, spinet, tumor growth rate, typical/atypical carcinoid,

#3266 The psychological impact of COVID-19 pandemic in patients with NETs: Between resilience and vulnerability

Introduction: The COVID-19 pandemic has dramatically changed lifestyles and quality of life (QoL) of the global population. Little is known regarding the psychological impact of COVID-19 in patients with gastroenteropancreatic (GEP) or bronchopulmonary (BP) NETs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lauricella E

Authors: Lauricella E, Cives M, Bracigliano A, Lamia S, Felici V,

Keywords: covid-19, net, depression, anxiety, quality of life,

#1939 Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors

Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Grabowski P

Authors: Lelek S, Sedding D, Benecke J, Siegmund B, Schrader J,

Keywords: Bronchopulmonary neuroendocrine tumors (BP-NET), somatostatin analogues, Lanreotide, signaling,

#1462 Cross-Talk Between EGFR and IGF1R Influences the Response to RTK Inhibitors in Bronchopulmonary (BP)-NET Cell Lines

Introduction: BP-NETs represent ~30% of all neuroendocrine tumors. BP-NET treatment is challenging due to onset of resistance to chemo and targeted therapies. EGFR and IGF1R had been associated with tumor onset and progression in several neoplasia.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gagliano T

Authors: Gagliano T, Gentilin E, Benfini K, Falletta S, Di Pasquale C,

Keywords: BP-NET RTK,